Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-03-15
2011-03-15
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S172100, C530S387900, C530S388100
Reexamination Certificate
active
07906120
ABSTRACT:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
REFERENCES:
patent: 5585089 (1996-12-01), Queen et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 6210671 (2001-04-01), Co
patent: 7612181 (2009-11-01), Wu et al.
patent: 2002/0012965 (2002-01-01), Strittmatter
patent: 90/05191 (1990-05-01), None
Groves 2000 (Hybridoma 19(3):201-214).
Babcock, John S. et al., “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities”, PNAS, (Jul. 1996), vol. 93, pp. 7843-7848.
Barton, William A. et al., “Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins”, The EMBO Journal, (May 2003), vol. 22 No. 13, pp. 3291-3302.
Bird, Robert E. et al., “Single-Chain Antigen-Binding Proteins”, Science, (May 1988), vol. 242(4877), pp. 423-426.
Carter, Paul et al., :“Humanization of an anti-p185HER2 antibody for human cancer therapy”, PNAS, (May 1992) vol. 89, pp. 4285-4289.
Domeniconi, M. et al., “Myelin-Associated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth”, Neuron, (Jul. 2002), vol. 35, pp. 283-290.
Fontoura, Paulo et al., “Nogo in multiple sclerosis: Growing roles of a growth inhibitor”, J. Neurol. Sci, (2006), vol. 245, pp. 201-210.
Fournier Alyson E. et al., “Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration”, Letters to Nature, (Jan. 2001), vol. 409, pp. 341-346.
Fournier Alyson E. et al., “Truncated Soluble Nogo Receptor Binds Nogo-66 and Blocks Inhibition of Axon Growth by Myelin”, The Journal of Neuroscience, vol. 22(20), pp. 8876-8883, 2002.
Fanger Michael W. et al., “Production and Use of Anti-FcR Bispecific Antibodies”, lmmunomethods, (1994), vol. 4, pp. 72-81.
Giege R. et al., “Crystallization of Nucleic Acids and Proteins, a Practical Approach”, 2nd. ea., (1999),pp. 20 1-16, Oxford University Press, New York, New York,.
Grandpre Tadzia et al., “Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein”, Letters to Nature, (2000), vol. 403, pp. 439-444.
Harlow Ed et al., “Antibodies a Laboratory Manual”, (1990), Cold Spring Harbor Press, New York:, Table of Contents Only.
Holliger Philipp et al., “Diabodies”: Small bivalent and bispecific antibody fragments, PNAS, (Jul. 1993), vol. 90, pp. 6444-6448.
Hunt David et al., “Nogo Receptor mRNA Expression in Intact and Regenerating CNS Neurons”, Molecular and Cellular Neuroscience, (2002), vol. 20, pp. 537-552.
Huston James S. et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”, (Aug. 1988), PNAS, vol. 85, pp. 5879-5883.
Johnsson Bo et al., “Immobilization of Proteins to a Carboxymethyldextran-Modified gold Surface for Biospecific Interaction Analysis in Surface Plasmon Resonance Sensors”, Analytical Biochemistry, (1991), vol. 198, pp. 268-277.
Johnsson Bo et al., “Comparison of Methods for Immobilization to Carboxymethyl Dextran Sensor Surfaces by Analysis of the Specific Activity of Monoclonal Antibodies”, Journal of Molecular Recognition, (1995), vol. 98, pp. 125-131.
Jonsson U. et al., “Real-time Biospecific Interaction Analysis Using Surface Plasmon Resonance and a Sensor Chip Technology”, BioTechniques, (1991), vol. 11 No. 5, pp. 620-627.
Jonsson U. et al., “Introducing a biosensor based technology for real-time biospecific interaction analysis”, Ann. Biol. Clin., (1993), vol. 51, pp. 19-26.
Kabat Elvin A. et al., “Sequences of Proteins of Immunological Interest” Fifth Edition (1991), U.S. Department of Health and Human Services, Maryland.
Kim Ji-Eun et al., “Nogo-66 Receptor Prevents Raphespinal and Rubrospinal Axon Regeneration and Limits Functional Recovery from Spinal Cord Injury”, Neuron, (Oct. 2004), vol. 44, pp. 439-451.
Kipriyanov, Sergey M. et al., “Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen”, Hum. Antibod. Hybridomas., (1995), vol. 6 (3), pp. 93-101.
Kipriyanov, Sergey M. et al., “Recombinant Single-chain Fv Fragments Carrying C-Terminal Cysteine Residues: Production of Bivalent and Biotinylated Miniantibodies”, Molecular Immunology, (1994), vol. 31 No. 14, pp. 1047-1058.
Kohler G. et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol. 256, pp. 495-497, 1975.
Lauren Juha et al., “Two novel mammalian Nogo receptor homologs differentially expressed in the central and peripheral nervous systems”, Molecular and Cellular Neuroscience, (May 2003), vol. 24, pp. 581-594.
Lee Daniel H. et al., “Targeting the Nogo Receptor to Treat Central Nervous System Injuries”, Nature Reviews, (Nov. 2003), vol. 2, pp. 1-7.
Mcgee Aaron W. et al., “The Nogo-66 receptor: focusing myelin inhibition of axon regeneration”, Trends in Neurosciences, (Apr. 2003)vol. 26, No. 4, page.
Mi Sha et al., “LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex”, Nature Neuroscience, (Mar. 2004), vol. 7 No. 3, pp. 221-228.
Padlan Eduardo A., “A Possible Procedure for Reducting the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties”, Molecular Immunology, (1991), vol. 28 No. 4/5, pp. 489-498.
Park Jong B. et al, “A TNF Receptor Family Member, TROY, Is a Coreceptor with Nogo Receptor in Mediating the Inhibitory Activity of Myelin Inhibitors”, Neuron, (Feb. 3, 2005), vol. 45, pp. 345-351.
Pignot V. et al., “Characterization of two novel proteins, NgRH1 and NgRH2, structurally and biochemically homologous to the Nogo-66 receptor”, Journal of Neurochemistry, (2003), vol. 85, pp. 717-728.
Poljak Roberto J, “Production and structure of diabodies”, Structure, (Dec. 15, 1994), vol. 2, pp. 1121-1123.
Presta, Leonard G. et al., “Humanization of an Antibody Directed Against IgE”, The Journal of Immunology, (Sep. 1, 1993), vol. 151, pp. 2623-2632.
Riechmann Lutz et al., “Reshaping human antibodies for therapy”, Nature, (Mar. 1988), vol. 332, pp. 323-327.
Robinson Joseph R., “Sustained and Controlled Release Drug Delivery Systems”, (Dec 1978), Marcel Dekker, Inc., New York.
Roguska Michael A. et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing”, PNAS, (Feb. 1994), vol. 91, pp. 969-973.
Shao Zhaohui et al., TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration, Neuron, (Feb. 3, 2005), vol. 45, pp. 353-359.
Studnicka Gary M. et al., “Human engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues”, Protein Engineering, (1994), vol. 7 No. 6, pp. 805-814.
Teng Felicia Yu Husan et al., “Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?”, Journal of Neurochemistry, (2005), vol. 94, pp. 864-874.
Venkatesh Karthik et al., “The Nogo-66 Receptor Homolog NgR2 Is a Sialic Acid-Dependent Receptor Selective for Myelin-Associated Glycoprotein”, The Journal o
Barlow Eve H.
Ghayur Tariq
Meyer Axel
Mezler Mario
Moeller Achim
Abbott Laboratories
Kolker Daniel E
Vepachedu Sreenivasarao
LandOfFree
Neutralizing monoclonal antibodies against the Nogo-66... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing monoclonal antibodies against the Nogo-66..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing monoclonal antibodies against the Nogo-66... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641061